GGrantIndex
← Search

Shared Resource: Genomics & Bioinformatics

$478,300P30FY2022CANIH

Fred Hutchinson Cancer Center, Seattle WA

Investigators

Linked publications & trials

Trial NCT06995898Trial NCT06682039Trial NCT06484595Trial NCT06193070Trial NCT05947500Trial NCT05930496Trial NCT05183828Trial NCT04902144Trial NCT04751383Trial NCT04682301Trial NCT04667481Trial NCT04660331Trial NCT04539366Trial NCT04505553Trial NCT04502524Trial NCT04500548Trial NCT04496219Trial NCT04489719Trial NCT04472338Trial NCT04466475Trial NCT04447313Trial NCT04444232Trial NCT04442581Trial NCT04431479Trial NCT04410900Trial NCT04387227Trial NCT04384692Trial NCT04383743Trial NCT04375631Trial NCT04372927Trial NCT04370301Trial NCT04359784Trial NCT04336943Trial NCT04329065Trial NCT04282187Trial NCT04260776Trial NCT04257578Trial NCT04254133Trial NCT04231877Trial NCT04220229Trial NCT04211766Trial NCT04208724Trial NCT04205409Trial NCT04200482Trial NCT04198922Trial NCT04196010Trial NCT04195945Trial NCT04195633Trial NCT04194918Trial NCT04188912Trial NCT04175431Trial NCT04156828Trial NCT04155840Trial NCT04151940Trial NCT04120246Trial NCT04111497Trial NCT04083183Trial NCT04083170Trial NCT04081779Trial NCT04081298Trial NCT04062955Trial NCT04060849Trial NCT03999515Trial NCT03991884Trial NCT03986502Trial NCT03980769Trial NCT03970096Trial NCT03907527Trial NCT03891784Trial NCT03864419Trial NCT03807063Trial NCT03806192Trial NCT03781778Trial NCT03779867Trial NCT03779854Trial NCT03778021Trial NCT03776864Trial NCT03749460Trial NCT03747484Trial NCT03737955Trial NCT03723863Trial NCT03718338Trial NCT03672981Trial NCT03670966Trial NCT03670069Trial NCT03660930Trial NCT03649841Trial NCT03641287Trial NCT03606486Trial NCT03602898Trial NCT03600038Trial NCT03585231Trial NCT03574012Trial NCT03570476Trial NCT03531918Trial NCT03525106Trial NCT03523195Trial NCT03522584Trial NCT03518242Trial NCT03516812

Abstract

PROJECT SUMMARY: GENOMICS & BIOINFORMATICS SHARED RESOURCE (G&BSR) The Genomics & Bioinformatics Shared Resource (G&BSR) is a state-of-the-art facility that has continued to evolve over the past 20 years, providing Cancer Consortium members with access to sophisticated, genomicsbased technologies and a team consisting of a highly experienced scientist, expert technical staff, and seasoned bioinformaticians. This team provides a seamless experience for the researcher, supporting all phases of technology selection, experimental design, sample QC, data generation, and analysis. The broad portfolio of massively parallel deep sequencing services offered through the G&BSR includes whole genome sequencing; whole exome sequencing; expression profiling of mRNAs, miRNAs, and non-coding RNAs; ribosome sequencing; and numerous targeted resequencing applications. Additionally, epigenomics services including the profiling of the DNA methylome, ATAC-seq, and Hi-C sequencing assays are performed. The G&BSR was also an early adopter of CRISPR-Cas9 pooled screens and supported the development of CUT&RUN – a protein-DNA interaction assay developed by Fred Hutch investigators, led by Dr. Steven Henikoff CBB , with both technologies now implemented as high-throughput pipelines available to the broader Consortium community through the G&BSR. In addition, the G&BSR routinely employs NanoString digital barcoding technology, conducts Sanger sequencing, and provides training on and access to qPCR instrumentation. Major equipment includes an Illumina NovaSeq 6000 sequencer, an lllumina HiSeq 2500 sequencer, two Illumina MiSeq sequencers, a Pacific Biosciences Sequel sequencer, an Illumina BeadChip system, a NanoString nCounter system, a 10x Genomics Chromium controller, two ABI 3730xl sequencers, a PerkinElmer Sciclone NGSx Workstation, and four ThermoFisher Scientific QuantStudio 5 real-time PCR systems. Peer-reviewed studies accounted for 66% of the work performed in the G&BSR during 2017 and staff contributed to over 30 publications (July 2017 – June 2018).

View original record on NIH RePORTER →